Although islet transplantation may restore insulin independence to individuals with type 1 diabetes mellitus, most have abnormal glucose tolerance. We asked whether the defective glucose tolerance is due to inadequate β-cell mass or to impaired insulin sensitivity. We performed metabolic studies on four cynomolgus primates before inducing diabetes with streptozotocin (STZ), then again 2-3 weeks after restoring insulin independence via intrahepatic islet transplantation utilizing a calcineurin inhibitor-free immunosuppressive regimen (induction with rabbit antithymocyte globulin and maintenance therapy with rapamycin). Engrafted β-cell mass was assessed by acute insulin and C-peptide responses to glucose (AIR glu and ACR glu ) and arginine (AIR arg and ACR arg ). Insulin sensitivity (S I ) was determined in naive and transplanted primates from an intravenous glucose tolerance test using the minimal model. α-Cell function was determined by the acute glucagon response to arginine (AGR arg ). Glucose tolerance (K g ) decreased from 4.1 ± 0.5%/min in naive primates to 1.8 ± 0.3%/min in transplanted primates (p < 0.01). Following transplantation, AIR glu was 28.7 ± 13.1 µU/ml compared to 169.9 ± 43.1 µU/ml (p < 0.03) in the naive condition, ACR glu was 14.5 ± 6.0 ng/ ml compared to 96.5 ± 17.0 ng/ml naive (p < 0.01), AIR arg was 29.1 ± 13.1 µU/ml compared to 91.4 ± 28.2 µU/ml naive (p < 0.05), and ACR arg was 1.11 ± 0.51 ng/ml compared to 2.79 ± 0.77 ng/ml naive (p < 0.05). S I did not differ from naive to posttransplant states. AGR arg was reduced in transplanted primates (349 ± 118 pg/ml) when compared to both naive (827 ± 354 pg/ml) and post-STZ diabetic primates (1020 ± 440 pg/ml) (p < 0.01 for both comparisons). These data suggest that impaired glucose tolerance observed in islet transplant recipients is secondary to low functional β-cell mass and not to insulin resistance shortly after transplant. Furthermore, improved glycemic control achieved via islet transplantation over the diabetic state might be attained, in part, via reduced glucagon secretion.
INTRODUCTION
islet transplantation regimens induce β-cell toxicity in both rodent and human islets (13, 30) . Metabolic studies of calcineurin inhibitor-free immunosuppressive regi-Islet transplantation is a promising way of restoring insulin independence to patients with type 1 diabetes mens for islet transplantation, however, are lacking. Our islet transplant model using nonhuman primates (NHPs) mellitus (T1DM) (8). When assessed by oral glucose tolerance testing, most islet transplant recipients do not afforded a unique opportunity to address the question since we could assess both islet function and insulin sen-regain normal metabolic control (6,29). Therefore, we asked whether the suboptimal glycemic control observed sitivity longitudinally (prior to diabetes onset, after diabetes induction, and again after receiving an islet following islet transplantation is due to inadequate islet β-cell mass or impaired insulin sensitivity. Recent evi-transplant with restored euglycemia while on rapamycin monotherapy). dence has shown that calcineurin inhibitors utilized in 1298 SOLEIMANPOUR ET AL.
MATERIALS AND METHODS
Metabolic Studies All procedures were performed using primates fasted Animals overnight. Primates were sedated with intramuscular Tela-The procedures described in this study were conzol (Fort Dodge Animal Health, Fort Dodge, IA) at a dose ducted according to the principles set forth by the of 3-6 mg/kg. The portacaths were accessed for blood National Research Council, and were approved by the sampling while an intravenous catheter was inserted into NIH Animal Care and Use Committee (IACUC).
the contralateral saphenous vein for infusions. The four islet donors were 8-10-year-old cynomol-Mixed Meal Stimulation Test. After basal blood samgus macaques (Macaca fascicularis, NIH nonhuman pripling, 30 ml of Ensure was administered via nasogasmate facility, Poolesville, MD) maintained on a regular tric tube. The primate was returned to its cage and primate diet with a continuous water supply and fresh retrieved at 90 min for another blood sample. fruits twice daily. Donors weighed 3.0-4.4 kg and were
Insulin Modified Frequently Sampled Intravenous ABO-compatible and major histocompatibility complex Glucose Tolerance Test. After two basal blood samples (MHC) mismatched to recipients. The four recipients were taken, an intravenous bolus of 0.27 g/kg glucose were a subgroup of previously studied Cynomolgus as a 50% solution was injected at time zero (t = 0 min), macaques (12) with an age range of 4.5-7 years and a and blood samples were drawn 2, 4, 8, and 19 min later. weight range of 2.4-3.1 kg. Vascular access was At 20 min, regular insulin (0.005 U/kg) was injected obtained by use of surgically implanted portacaths into intravenously. Further blood samples were drawn at 22, each primate's internal jugular veins at least 2 weeks 30, 40, 50, 70, 90, and 180 min. prior to initial metabolic testing.
Diabetes was induced as described previously by Arginine Stimulation Test. After two basal blood selectively infusing 70 mg/kg body weight streptosamples, 2 g arginine (as a 10% solution) was infused zotocin (STZ, Pharmacia & Upjohn) directly into the by intravenous bolus and blood samples were then taken pancreatic arterial bed to result in selective β-cell at 2, 3, 4, 5, 7, 10, and 15 min later. destruction (32). Diabetes was maintained for at least 1 Sample Handling month and absolutely deficient endogenous insulin production was then confirmed by a negative C-peptide Blood samples were collected in chilled tubes and response to an arginine stimulation test. Diabetic pricentrifuged soon afterwards. Serum samples were mates were treated with 2-3 U/kg body weight of glardecanted and frozen at −70°C for later insulin, C-pepgine insulin (Lantus) injected each morning. Fasting tide, and glucagon assays and plasma was frozen at and postprandial glucose levels were monitored by three −70°C for glucose, glycerol, and free fatty acid assays. daily tail stick measurements.
Biochemical Determinations Pancreases were procured from donor primates and islet isolation was performed using the automated and Glucose was measured in plasma using the glucose Liberase-based method for human islet isolation (28) . oxidase method. Serum insulin and C-peptide were mea-Islets were surgically infused into the portal vein sured using a commercially available human ELISA through a branch of the superior mesenteric vein as pre-(Alpco Diagnostics, Wyndham, NH), and glucagon was viously described (11) . To prevent graft rejection, primeasured using a commercially available radioimmunomates were treated with rabbit antithymocyte globulin assay (RIA) kit (Linco diagnostics, St. Charles, MO). (rATG) (Thymoglobulin Sangstat, CA) and rapamycin Plasma glycerol was assessed by an enzymatic calori-(sirolimus) (Rapamune, Wyeth-Ayerst) (12) . rATG (20 metric assay (Sigma Diagnostics, St. Louis, MO). mg/kg) was administered intravenously daily for 7 days, Plasma free fatty acids were assessed enzymatically with the first dose given immediately prior to transplan-(Wako Chemicals, Richmond, VA). All assays were pertation. Rapamycin was given once a day orally, to target formed in duplicate. 24-h trough levels of 10-15 ng/ml and measured weekly Calculations as previously described (12) .
Metabolic studies were completed in the naive state Insulin sensitivity (S I ) and glucose effectiveness (S G ) (2-4 weeks prior to STZ-induced diabetes), 2 weeks were calculated from glucose and insulin values during post-diabetes induction, and 14-20 days following islet the IVGTT using the minimal model of glucose kinetics transplantation. Only arginine stimulation testing was
(2). The acute insulin response to glucose (AIR glu ) was performed post-diabetes induction to prevent severe computed from the insulin levels during the IVGTT as hyperglycemia due to the mixed meal tolerance test or the integrated incremental insulin concentrations above intravenous glucose tolerance test (IVGTT).
basal levels obtained during the first 10 min. Glucose disappearance (K g ) was calculated as the slope of the line IVGTT plotting the natural logarithm of glucose values between 4
The mild posttransplant glucose intolerance observed and 19 min of the IVGTT versus time. The acute C-pepduring mixed meal tolerance testing was also observed tide response to glucose (ACR glu ) during the IVGTT was during the IVGTT, with significant reductions in glucalculated as the incremental area under the curve (AUC) cose tolerance as assessed by the glucose disposal rate using the trapezoidal rule for the first 19 min of the (K g ) in the transplanted group ( Fig. 2A , Table 2 ). The IVGTT. The disposition index (DI) was calculated as the first phase insulin and C-peptide responses were diminproduct of AIR glu (in pmol/L) and S I (14) . Data were calcuished in primates following islet transplantation comlated using the MINMOD 3 software (25) . pared to the same primates before diabetes was induced The acute insulin response to arginine (AIR arg ) and ( Fig. 2B, C) . This is best demonstrated by the acute acute C-peptide response to arginine (ACR arg ) were insulin response to glucose (AIR glu ), which was diminquantified as mean incremental increases above baseline ished 83.3% from baseline (Table 2) . Similarly, the levels within the first 5 min following arginine injection.
acute C-peptide response to glucose (ACR glu ) was 96.5 ± The acute glucagon response to arginine (AGR arg ) was 17.0 ng/ml in naive primates but only 14.5 ± 6.0 ng/ml quantified as the incremental AUC for glucagon levels in the transplant group (p < 0.01). Minimal modelfrom 2 to 7 min following arginine injection.
derived S I and S G values calculated from the IVGTT data were not different among the groups ( Table 2 ). The Statistical Analysis impaired first-phase insulin secretion (whether measured Comparisons of experimental determinations between by AIR glu or ACR glu ) best explains the decreased glucose groups were made utilizing ANOVA, followed by Bonfdisappearance rate (K g ) seen in the transplanted group as erroni post hoc tests, and two-tailed Student's t-tests.
neither insulin sensitivity (S I ) nor glucose effectiveness Results are expressed as means ± SEM unless other-(S G ) was impaired. When comparing the native to the wise noted. posttransplantation state, the calculated disposition index (DI) was significantly reduced (Table 2) , further RESULTS
suggesting that the β-cells are not compensating ade-All primates (n = 4) were rendered C-peptide negaquately for the prevailing insulin sensitivity. tive following intra-arterial STZ. C-peptide-negative Consistent with the lower circulating insulin levels diabetes was confirmed by repeated fasting glucose levfound in the animals post-islet transplant, we observed els above 250 mg/dl, and, 1 month later, by nonmeasurthat while naive animals show the expected decline in able C-peptide secretion in response to an arginine plasma free fatty acid (FFA) and glycerol levels in a stimulation test. Following islet transplantation with fashion parallel to insulin secreted during the IVGTT, 9,215 ± 2,420 IEQ/kg body weight, all primates were transplanted primates show no such decrease in FFA and rendered insulin independent with excellent glycemic glycerol ( Fig. 2D, E) . control, as previously described (12) ( Table 1 ). The ani-Arginine Stimulation Test mals' average weight prior to diabetes induction was 2.7 kg, after diabetes induction the average weight was
The acute insulin response to arginine (AIR arg ) was unchanged, and after islet transplant the animals' weight reduced from 91.4 ± 28.2 µU/ml in naive primates (n = ranged from 2.5 kg (min) to 2.6 kg (max). The most 8, including donors) to 29.1 ± 13.1 µU/ml in transplanted extreme weight loss occurred in an animal that weighed primates (n = 4, p < 0.05). Similarly, ACR arg was reduced 3.1 kg prior to diabetes onset, 2.85 kg after diabetes from 2.79 ± 0.77 ng/ml in naive primates to 1.11 ± 0.51 induction, and a nadir of 2.6 kg following islet transplant ng/ml in the transplanted primates (p < 0.05). with recovery to 2.75 kg at autopsy. All recipients had Consistent with previous reports (34), we observed a supratherapeutic trough rapamycin levels (15-30 ng/ml) robust glucagon response to arginine in the diabetic during the time period of metabolic studies (12) . state; however, the glucagon response was markedly reduced following islet transplantation (Fig. 3) . The Mixed Meal Stimulation Test AGR arg was 827 ± 354 pg/ml in the naive state and 1,020 Insulin and C-peptide values between the naive (n = ± 440 pg/ml in the post-STZ diabetic state with a signifi-8, including donors) and transplanted (n = 4) primates cant decline to 349 ± 118 pg/ml in the posttransplantawere comparable at both 0 and 90 min. Fasting glucose tion state (p < 0.01 for both comparisons). values between the groups were also similar. However, DISCUSSION at 90 min, glucose values were higher in transplanted primates compared to naive primates (138.6 ± 3.7 vs.
We demonstrate here through reductions in the acute insulin and C-peptide responses to glucose and arginine 66.5 ± 6.8 mg/dl) (p < 0.01) (Fig. 1) . that a low islet β-cell mass relative to the naive state is the principal cause of the impaired glucose tolerance observed following intrahepatic islet transplantation. Furthermore, rapamycin monotherapy is not associated with insulin resistance in the early posttransplant period. Finally, our results demonstrate that the improved glycemic control following engraftment of a suboptimal islet mass may be achieved, in part, through suppression of glucagon secretion. The apparent reduction in islet function we observe in transplanted primates may be due to mechanisms other than reduced functional β-cell mass. Reductions in circulating insulin concentration could result from increased insulin extraction by the liver. This is not likely, however, as human recipients of intrahepatic islet transplant have been reported to have both normal insulin-mediated suppression of hepatic glucose production and hepatic insulin extraction (20, 22) , as well as our observations of reduced C-peptide levels, which is unaffected by liver extraction and not disproportionately different than insulin levels in this study. Our primates did have elevated systemic rapamycin levels (12) , possibly inhibiting islet function. Unfortunately, consistent rapamycin levels were difficult to maintain (11) because of reluctance of the animals to take oral rapamycin and due to its gastrointestinal toxicities (24) . As orally administered rapamycin results in a 1.65-fold higher drug concentration in portal relative to peripheral vein blood, islets infused into the portal vein are exposed to slightly higher sirolimus concentrations (5). Supratherapeutic sirolimus concentrations have been shown to have a deleterious effect on rat and human islets in vitro (1), and on rat islet function in vivo (19) . On the other hand, the improved insulin secretion shown in minipigs treated with sirolimus in vivo, as well as the extremely low incidence of diabetes reported in human nonislet transplant recipients treated with sirolimus in the absence of glucocorticoids, both suggest that sirolimus may not cause significant islet functional impairment (15, 21) .
Islet functional assays may also be limited by a relative lack of vascular supply of the transplanted islets. Revascularization of islets in primates may take between 7 and 30 days following transplant (10) and within 10-14 days in rodents (3,23). It is possible, therefore, that our studies were performed at a time when revascularization has occurred. If this is not the case, it is still that ongoing rejection contributed to the abridged islet function, as we did not observe lymphocyte infiltration surrounding or penetrating the transplanted islets (12) . We assessed insulin sensitivity by the minimal model remain near their minimum as glucose increases above basal levels. Only after insulin concentrations begin to of glucose kinetics to calculate the S I , a mathematical index of insulin sensitivity that has been extensively val-fall do the FFA and glycerol levels rise. In contrast, neither the FFA nor the glycerol levels decline below basal idated in rodents and multiple large animal models, including nonhuman primates (2,4). The S I data obtained levels in the transplant group. Therefore, it is possible that the islets of transplanted primates produce just from the IVGTT suggest that while islet mass is reduced, insulin sensitivity remains unchanged between enough insulin to control blood glucose but insufficient insulin to inhibit lipolysis in peripheral tissues. These the naive and transplanted animals and so is unaffected by rapamycin treatment. Nonetheless, the FFA and glyc-findings are in contrast to those observed in human islet transplant recipients, who demonstrate the expected erol responses observed during the IVGTT provide further insight into islet function postislet transplantation.
insulin-mediated suppression of FFAs (9,27). These distinct differences may potentially suggest that nonhuman Insulin's well-described antilipolytic effects inhibit triglyceride breakdown to its products, FFA, and glycerol.
primates exhibit a greater impairment in insulin-mediated inhibition of lipolysis over that of glucose disposal In naive primates, we observed a rapid decline in FFA and glycerol levels soon after insulin concentrations rise in the setting of impaired insulin secretion. On the other hand, these effects may be related to rapamycin therapy, during the IVGTT. In fact, FFA and glycerol levels for their advice. We wish to acknowledge the excellent husas rapamycin has been shown to increase lipolysis and abnormalities (17) . Further, patients with insulinopenic
